ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1593	National Cancer Institute	Html	en	Mistletoe Extracts (PDQ®)–Health Professional Version	Mistletoe, a semiparasitic plant that grows on several types of trees such as apple, oak, pine and elm, is commonly used in cancer patients in Europe. Read about laboratory and human studies of extracts, such as Iscador and Eurixor, and their effects on quality of life, survival and symptom relief in this expert-reviewed summary.	aqueous mistletoe extract 0.442009 mistletoe lectin-1-standardized extract 0.441439 mistletoe extracts 0.647935 recombinant mistletoe lectin 0.458451 Viscum album var. 0.395649 viscum album 0.915234 viscum album extracts 0.415076 Viscum album L. 0.758622 mistletoe preparations 0.534599 orally administered mistletoe 0.439154 breast cancer patients 0.419485 galactoside-specific mistletoe lectin 0.506693 patients 0.47671 cancer patients 0.474171 mistletoe 0.798357 lectin standardized mistletoe 0.506505 galactoside-specific lectin 0.442636 galactoside-binding mistletoe lectin 0.510133 adjuvant mistletoe treatment 0.475546 mistletoe lectin-induced apoptosis 0.437043 mistletoe treatment programme 0.472546 et al. 0.450682 mistletoe lectin ML-1 0.486886 Korean mistletoe lectin 0.477775	mistletoe treatment 0.507798 PUBMED Abstract 0.60337 mistletoe extract 0.555931 Purified mistletoe lectins 0.438108 Viscum album extract 0.453589 different mistletoe preparations 0.423047 Anticancer Res 0.416126 galactoside-specific mistletoe lectin-1 0.433265 mistletoe’s ability 0.439494 blood mononuclear cells 0.426242 standardized mistletoe extracts 0.436989 Gabius HJ 0.430845 European mistletoe 0.545426 mistletoe lectin-II-induced apoptosis 0.4369 breast cancer 0.430552 aqueous mistletoe preparations 0.463767 mistletoe lectins 0.543537 Viscum album preparation 0.39341 unfermented mistletoe preparations 0.438537 iscador 0.417024 mistletoe extract Iscar 0.429817 mistletoe lectin 0.642042 cancer 0.50332 standardized mistletoe extract 0.492996	CLICK HERE
1714	National Cancer Institute	Html	en	Computed Tomography (CT) Scans and Cancer	A fact sheet that describes the CT scan procedure and technology and its uses in screening, diagnosis, and treatment.	CT imaging technology 0.569562 regular-dose CT scan 0.562007 lung cancer screening 0.54026 CT procedure 0.731231 newest CT scanners 0.587346 whole-body CT 0.57001 ct exams 0.558916 CT procedures 0.54984 lung cancer 0.592986 radiation dose 0.50377 health care providers 0.544231 multislice CT 0.569592 U.S. Food 0.504864 Lung Screening Trial 0.488364 single CT scan 0.559043 ct colonography 0.665422 colorectal cancer 0.498955 older CT techniques 0.588973 Tracking radiation exposure 0.48666 multiple CT scans 0.560065 standard CT 0.559346 National CT Colonography 0.621292 helical CT procedure 0.596247 low-dose CT scan 0.568401	average annual dose 0.483921 CT scanner manufacturers 0.553452 CT scans 0.582194 low-dose helical CT 0.69526 radiation risks 0.502098 Drug Administration 0.507156 radiation exposure 0.603574 modern CT machines 0.590707 American College 0.525134 original CT machines 0.590542 CT imaging 0.587843 National Lung Screening 0.489052 external-beam radiation therapy 0.487398 people 0.506505 natural background radiation 0.502791 CT 0.922359 radiation dose exposures 0.484749 radiation 0.608408 Unnecessary Radiation Exposure 0.486946 cancer risk 0.502536 cancer 0.609695 CT scanners 0.63294 multidetector CT scanners 0.588732 typical CT procedure 0.581742	CLICK HERE
1886	National Cancer Institute	Html	es	Tratamiento de la micosis fungoide (incluso el síndrome de Sézary) (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de la micosis fungoide (incluso el síndrome de Sézary).	mycosis fungoides patients 0.11169 with cutaneous t-cell 0.128234 Dummer R 0.111348 Syndrome With Variable 0.114584 mycosis fungoides 0.97928 beam therapy with 0.111374 mycosis fungoides with 0.131223 patients with refractory 0.123614 patients with mycosis 0.138673 refractory mycosis fungoides 0.123051 Sézary Syndrome With 0.116656 lymphomas with cutaneous 0.112178 Am Acad Dermatol 0.337245 Cutaneous Lymphoma Consortium 0.148918 Lymphoma Study Group 0.112378 cutaneous lymphoma 0.228697 fungoides with twice-weekly 0.112255 Radiat Oncol Biol 0.152639 treatment refractory cutaneous 0.111862 with erythrodermic cutaneous 0.112109 Hematol Oncol Clin 0.121844 United States Cutaneous 0.120966 cutaneous lymphoma international 0.128062 patients with 0.427189 Total skin 0.115055	patients treated with 0.1213 with cutaneous 0.12999 Arch Dermatol 0.198688 cutaneous t-cell lymphoma 0.78168 with refractory cutaneous 0.113675 States Cutaneous Lymphoma 0.140249 Duvic M 0.128091 Kim YH 0.150166 with cutaneous manifestations 0.111847 initial treatment 0.113809 sézary syndrome 0.418227 T-cell lymphomas with 0.111442 refractory cutaneous t-cell 0.128365 Lymphoma Myeloma Leuk 0.11766 fungoides with photochemotherapy 0.112499 Guitart J 0.113207 Clin Oncol 0.349784 lymphoma international prognostic 0.112345 Oncol Biol Phys 0.155154 patients with cutaneous 0.128063 Clin North Am 0.119374 Lymphoma International Consortium 0.112352 Oncol Clin North 0.121296 Zackheim HS 0.112943	CLICK HERE
1902	National Cancer Institute	Html	es	Tratamiento de los tumores neuroendocrinos de páncreas (tumores de células de los islotes) (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento de los tumores de células de los islotes (páncreas endocrino).	siguientes procedimientos 0.350148 causa dolores 0.307246 siguientes aspectos 0.303943 páncreas causa efectos 0.320993 pequeña cantidad 0.31153 células endocrinas 0.3138 causa debilidad 0.302846 oclusión arterial hepática 0.351832 siguientes tipos 0.303556 vía oral 0.301543 rayos x 0.302476 pequeños electrodos 0.301441 ondas sonoras 0.302366 tumores neuroendocrinos 0.984556 glucagón causa hiperglucemia 0.306311 tne pancreático 0.315238 siguientes riesgos 0.300896 tratamiento quizás 0.303501 endocrina múltiple tipo 0.305298	Instituto Nacional 0.302944 PDQ Tratamiento 0.311878 Colangiopancreatografía retrógrada 0.302587 Medicamentos bloqueadores 0.301556 TNE funcionantes 0.308747 partes distantes 0.304229 siguientes factores 0.304155 Physician Data Query 0.302879 tumores endocrinos 0.310974 causa sensación 0.302849 final angosto 0.303102 siguientes enlaces 0.301371 Alto contenido 0.302594 Ecografía intraoperatoria 0.302362 Baja concentración 0.302446 pancreatectomía distal 0.304071 siguientes pruebas 0.304812 largo tiempo 0.302722	CLICK HERE
1952	National Cancer Institute	Html	es	Tratamiento de las neoplasias de células plasmáticas (incluso mieloma múltiple) (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento de las neoplasias de células plasmáticas (incluso mieloma múltiple).	siguientes procedimientos 0.346148 células madre 0.945416 causa signos 0.305542 trasplante autógeno 0.329369 suficientes glóbulos 0.313511 siguientes cambios 0.312466 suficientes células 0.367406 células madre formadoras 0.329864 siguientes tipos 0.318034 siguientes fases 0.308352 rayos x 0.307538 causa hipercalcemia 0.310068 sumario tratamiento 0.33895 células anormales.ampliar aspiración 0.361154 causa problemas 0.309382 Nuevas combinaciones 0.305801 lesiones óseas 0.305545 National Cancer Institute 0.305225 siguientes riesgos 0.305748 células plasmáticas.Gammapatía 0.37332	Multiple Myeloma 0.338693 Instituto Nacional 0.318628 Plasma Cell Neoplasms 0.366703 PDQ Tratamiento 0.31456 presente sección 0.305256 beta-2 microglobulina 0.490964 Drugs Approved 0.337847 siguientes signos 0.334405 estudio regímenes 0.30494 Physician Data Query 0.319252 estadio iii 0.3425 proteína m 0.36173 inhibidor hdac 0.307303 siguientes enlaces 0.307028 células sanguíneas maduras 0.372655 células b 0.368037 siguientes pruebas 0.314313 siguientes sumarios 0.313298 Other Plasma Cell 0.367102	CLICK HERE
2040	National Cancer Institute	Html	es	Exámenes de detección del cáncer de piel (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca de las pruebas que se utilizan para detectar sistemáticamente el cáncer de piel.	antecedentes familiares 0.452736 nevo atípico 0.361408 almacena agua 0.367337 lámparas solares 0.360685 PDQ Exámenes 0.39849 Physician Data Query 0.505569 mayores probabilidades 0.363001 radiación uv 0.621972 Estados Unidos 0.932757 simple vista 0.348992 prevención revisa 0.335498 Skin Cancer 0.36265	siguientes ejemplos 0.362131 luz solar 0.675106 información ayuda 0.338156 vitamina d 0.367339 Características genéticas 0.361581 National Cancer Institute 0.353374 siguientes riesgos 0.336165 piel melanoma 0.814223 radiación ultravioleta 0.507855 siguientes sumarios 0.40536 Instituto Nacional 0.399902	CLICK HERE
2077	National Cancer Institute	Html	es	Pruebas genéticas para síndromes hereditarios de cáncer	Trata de pruebas genéticas para riesgos heredados de cáncer; incluye tipos de pruebas, para quién son, explicación y confidencialidad de los resultados. Ofrece información de pruebas genéticas a domicilio o pruebas para el consumidor.	paciente grupos 0.426785 ningún efecto 0.430963 direct-to-consumer genetic testing 0.524243 Clinical Chemistry 0.427805 Privacy Rule 0.424134 Accountability Act 0.423749 gen mutante 0.448711 Clinical Laboratory Improvement 0.443406 copia mutante 0.438081 seguro médico 0.523691 valiosa oportunidad 0.42438 gen alteraciones 0.444199 Topol E 0.422575 profesionales genéticos 0.423689 información genética 0.694265 PubMed Abstract 0.469151 PMC Article 0.422751 pruebas genéticas caseras 0.933419 Clinical Oncology 0.46864 reliable or risky 0.440953 GWAS) por medio 0.422097 pequeña porción 0.422164 hijo hereda 0.4346 leyes gina 0.4236 determinada persona 0.471237	profesional conocedor 0.425068 negativo carente 0.503682 Health Information Portability 0.441872 cuidado preventivo 0.422328 Clinical Oncology Policy 0.44516 ASHG statement 0.425726 genomic testing 0.424164 conocida mutación 0.495717 falsa seguridad 0.422355 Genética Humana 0.494712 Javitt G 0.4224 Federal Trade Commission 0.438077 Human Genetics 0.422666 cabo pruebas 0.510628 antecedentes familiares 0.466262 pruebas quizás 0.52233 posibles alternativas 0.424779 complicada decisión 0.427954 estudios por asociación 0.422415 profesional genético 0.434126 negativo falso 0.497922 hijos hombres 0.425049 llama portadores 0.430487 llamadas polimorfismos 0.425347	CLICK HERE
3563	National Cancer Institute	Html	en	Jonathan S. Wiest, Ph.D.	Dr. Jonathan S. Wiest obtained a bachelor’s degree in analytical chemistry from the University of Wisconsin-Milwaukee in 1980.	North Carolina 0.409045 Wisconsin-Milwaukee 0.254953 Merit 0.234346 Cincinnati 0.232275 Associate Director 0.407274 lung cancer 0.424227 tumor suppressor genes 0.574882 Department 0.23225 major training activities 0.564519 Ph.D. 0.233553 Jonathan S. Wiest 0.863013 Distinguished Service Award 0.551249 graduate school 0.424709 rank 0.235426 Dr. Wiest 0.997677 Senior Staff Fellow 0.581562 Environmental Health 0.594668 National Postdoctoral Association 0.552911 P-L Biochemicals 0.44241 Cancer Training 0.545462 degree 0.236458 pathways 0.234519 oligonucleotides 0.254305 major focus 0.390603	University 0.266416 Research Triangle Park 0.595619 lung tumorigenesis 0.406774 Environmental Health Sciences 0.585151 analytical chemistry 0.428974 Cancer Research Institute 0.616451 annual meeting 0.38327 National Cancer Institute 0.597756 NCI Outstanding Mentor 0.614163 production chemist 0.439071 assistant professor 0.400629 National Institute 0.418588 western Colorado 0.405661 Center 0.289661 bachelor 0.23726 NCI Director 0.467597 genetic alterations 0.402361 Medical College 0.424659 extramural communities 0.42187 NIH Director 0.428955 CCT 0.328048 Ohio 0.235704 Toledo 0.23553 NIH Award 0.427672	CLICK HERE
3674	National Cancer Institute	Html	en	About the Genomic Data Sharing (GDS) Policy	Find helpful information about the GDS Policy, including when the policy applies, example projects, and providing informed consent.	data 0.82822 subsequent research 0.542062 scale research projects 0.540547 case-by-case basis 0.523592 large-scale genomic data 0.566607 research 0.652936 research projects 0.576167 intramural research 0.556456 investigators 0.50707 future research 0.572423 genomic data 0.760118 Human Genome Research 0.527144 Sharing Repository list 0.531325 NIH repository 0.489091 research community 0.487992 non-human genomic data 0.67956 NIH-funded research projects 0.531999 broad sharing 0.547642 Intramural investigators 0.494528 Trans-NCI Data Sharing 0.55358 NIH Genomic Data 0.603222 NIH Deputy Director 0.524095 usual data 0.490789 data sharing 0.652134	NCI Scientific Program 0.534443 Rare Disease Act 0.50658 United States 0.504978 sample consent forms 0.527036 NCI-funded research 0.492053 small patient populations 0.504923 sample threshold 0.505219 alternative data sharing 0.62573 appropriate program directors 0.511229 appropriate NCI Program 0.550878 Phenotypic Data Subject 0.531651 intramural scientific director 0.629908 consent forms 0.555547 data sharing plan 0.62329 effective date 0.571535 smaller scale 0.517774 study data 0.489242 NCI Director 0.488407 NIH-designated data repositories 0.533934 data repositories 0.543247 Intramural projects 0.499743 gds policy 0.963933 time points 0.50548 Orphan Drug Act 0.506071	CLICK HERE
16840	National Cancer Institute	Html	en	Companies Formed by PIs of the NCI Alliance for Nanotechnology in Cancer	The NCI Alliance for Nanotechnology in Cancer has continued to translate solutions from the bench to products. Find out the companies that have been formed by Alliance funded research.	clinical products 0.627038 Alliance members 0.614849 academic laboratories 0.654334 for-profit partners 0.714957 start-ups 0.300298 clinical communities 0.60175 venture capital funds 0.950483 investigators 0.301645 partnerships 0.289977 start-up companies 0.650807 patents 0.29414 large pharmaceutical companies 0.926075	translational research 0.68727 significant investment 0.618191 Alliance PIs 0.780886 efficient development 0.679103 IP 0.327964 Alliance model 0.651092 services 0.276826 start-up companies. 0.723832 technologies 0.28746 biotechnology firms 0.63767 form 0.28731 discoveries 0.300415	CLICK HERE